145 related articles for article (PubMed ID: 21942285)
1. Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression.
Tembhare P; Yuan C; Korde N; Maric I; Landgren O
Leuk Lymphoma; 2012 Apr; 53(4):721-4. PubMed ID: 21942285
[No Abstract] [Full Text] [Related]
2. CD38 expression by plasma cells in extramedullary multiple myeloma.
Notarfranchi L; Accardi F; Mancini C; Martella E; Bonomini S; Segreto R; Vescovini R; Palma ABD; Sammarelli G; Todaro G; Storti P; Burroughs-Garcia J; Iannozzi NT; Raimondi V; Lungu O; Ricci S; Craviotto L; Giuliani N
Haematologica; 2024 Apr; 109(4):1297-1300. PubMed ID: 37941401
[No Abstract] [Full Text] [Related]
3. Double CD38
Mykytiv V; Alwaheed A; Mohd Hashim NA
Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):64-66. PubMed ID: 29079129
[TBL] [Abstract][Full Text] [Related]
4. DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.
Choudhry P; Mariano MC; Geng H; Martin TG; Wolf JL; Wong SW; Shah N; Wiita AP
Leukemia; 2020 Mar; 34(3):938-941. PubMed ID: 31595037
[No Abstract] [Full Text] [Related]
5. CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy.
Minarik J; Novak M; Flodr P; Balcarkova J; Mlynarcikova M; Krhovska P; Pika T; Pikalova Z; Bacovsky J; Scudla V
Eur J Haematol; 2017 Aug; 99(2):186-189. PubMed ID: 28470777
[TBL] [Abstract][Full Text] [Related]
6. Myelomatous pleural effusion with plasmablastic morphology and high genetic complexity as isolated extramedullary relapse.
Martín-Moro F; Roncancio A; Benito A; Talavera M; Villarrubia J; Blanchard MJ
Ann Hematol; 2020 Nov; 99(11):2705-2706. PubMed ID: 32458065
[No Abstract] [Full Text] [Related]
7. VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months.
Courville EL; Yohe S; Shivers P; Linden MA
Am J Clin Pathol; 2020 Jan; 153(2):221-228. PubMed ID: 31679012
[TBL] [Abstract][Full Text] [Related]
8. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
[TBL] [Abstract][Full Text] [Related]
9. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
[TBL] [Abstract][Full Text] [Related]
10. VS38 as a promising CD38 substitute antibody for flow cytometric detection of plasma cells in the daratumumab era.
Mizuta S; Kawata T; Kawabata H; Yamane N; Mononobe S; Komai T; Koba Y; Ukyo N; Tamekane A; Watanabe M
Int J Hematol; 2019 Sep; 110(3):322-330. PubMed ID: 31183814
[TBL] [Abstract][Full Text] [Related]
11. C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies.
Kraj M; Pogłód R; Kopeć-Szlezak J; Sokołowska U; Woźniak J; Kruk B
Leuk Lymphoma; 2004 Nov; 45(11):2281-9. PubMed ID: 15512818
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
[TBL] [Abstract][Full Text] [Related]
13. Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells.
Ak I; Aslan V; Vardareli E; Gülbaş Z
Ann Hematol; 2003 Feb; 82(2):88-92. PubMed ID: 12601486
[TBL] [Abstract][Full Text] [Related]
14. Expression of interleukin-11 receptor in CD38-positive cells from patients with multiple myeloma.
Tsimanis A; Shtalrid M; Shvidel L; Kalinkovich A; Berrebi A; Klepfish A
Leuk Lymphoma; 2004 Nov; 45(11):2315-9. PubMed ID: 15512823
[TBL] [Abstract][Full Text] [Related]
15. Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.
Hu Y; Liu H; Fang C; Li C; Xhyliu F; Dysert H; Bodo J; Habermehl G; Russell BE; Li W; Chappell M; Jiang X; Ondrejka SL; Hsi ED; Maciejewski JP; Yi Q; Anderson KC; Munshi NC; Ao G; Valent JN; Lin J; Zhao J
Cancer Res; 2020 May; 80(10):2031-2044. PubMed ID: 32193289
[TBL] [Abstract][Full Text] [Related]
16. CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon.
Laubach JP; Richardson PG
Clin Cancer Res; 2015 Jun; 21(12):2660-2. PubMed ID: 25878332
[TBL] [Abstract][Full Text] [Related]
17. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell.
Billadeau D; Ahmann G; Greipp P; Van Ness B
J Exp Med; 1993 Sep; 178(3):1023-31. PubMed ID: 8350044
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis.
McSweeney PA; Wells DA; Shults KE; Nash RA; Bensinger WI; Buckner CD; Loken MR
Blood; 1996 Jul; 88(2):622-32. PubMed ID: 8695810
[TBL] [Abstract][Full Text] [Related]
19. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy.
Sanoja-Flores L; Flores-Montero J; Puig N; Contreras-Sanfeliciano T; Pontes R; Corral-Mateos A; García-Sánchez O; Díez-Campelo M; Pessoa de Magalhães RJ; García-Martín L; Alonso-Alonso JM; García-Mateo A; Aguilar-Franco C; Labrador J; Barez-García A; Maiolino A; Paiva B; San Miguel J; Sobral da Costa E; González M; Mateos MV; Durie B; van Dongen JJM; Orfao A
Blood; 2019 Dec; 134(24):2218-2222. PubMed ID: 31697808
[No Abstract] [Full Text] [Related]
20. Characterization of a novel interleukin-6 autocrine-dependent human plasma cell line.
Ozaki S; Wolfenbarger D; deBram-Hart M; Kanangat S; Weiss DT; Solomon A
Leukemia; 1994 Dec; 8(12):2207-13. PubMed ID: 7528862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
